Status
Conditions
About
The study is aimed at evaluating the efficacy and tolerability of systemic pharmacotherapy as a part of combination treatment, and its influence on the overall treatment outcomes in patients with skin changes (CEAP class C4a and C4b).
Full description
Primary goal:
To study the efficacy of systemic pharmacotherapy as part of combination therapy and its impact on the:
Secondary goals:
To study the efficacy of systemic pharmacotherapy as part of combination therapy and its impact on the:
To evaluate the changes in the quality of life using the CIVIQ-14 questionnaire (global index score [GIS]) .
To study the tolerability of systemic pharmacotherapy as part of combination therapy in patients with skin changes of CEAP class C4a or C4b.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Treatment with drugs potentially causing leg edema (calcium channel blockers, hormonal drugs, NSAIDs, etc.) History of deep vein thrombosis (within the past year) History of superficial thrombophlebitis (within the past 3 months) History of surgical intervention (within the past 3 months) Patient cannot walk (regardless of the cause) Predictable poor adherence to treatment Participation of a patient in the intervention study within the previous 3 months For women: pregnancy or breastfeeding, the desire to become pregnant within at least 2 months after the study Patients with a contraindication to diosmin-containing agents, including Detralex Patient uses the topical treatments contraindicated in case of skin integrity violation.
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal